Literature DB >> 15744814

Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.

Seong-Hwan Moon1, Kyoo-Ho Shin, Jin-Suck Suh, Woo-Ick Yang, Jae-Keong Noh, Soo-Bong Hahn.   

Abstract

Change in tumor volume after chemotherapy appears to have a prognostic significance for the outcome of osteosarcoma. A newly developed volume measurement method based on three-dimensional summation with a proved reproducibility was utilized to measure osteosarcoma tumor volume. This retrospective analysis included 38 patients with biopsy- proven, nonsurface, skeletal high-grade osteosarcoma. The treatment was started by using three cycles of preoperative chemotherapy with cisplastin (100 mg/m2) and adriamycin (30 mg/m2). The tumor volume was measured before and after preoperative chemotherapy using three-dimensional magnetic resonance image measurement. The percentage of tumor necrosis was assessed by pathologic exam. After three cycle of postoperative chemotherapy, the patients were followed up at regular interval. For the 23 good responder patients, the mean survival time was 73.2 months (95% confidence interval 61.9-84.5 months), and for the 15 poor responder patients, the mean survival time was 50.8 months (95% confidence interval 38.6-63.1 months) (p<0.05). For the 14 patients with increased tumor volume after chemotherapy, the mean survival time was 47.5 months (range: 36.3-58.6 months) and for the 24 patients with stable or decreased tumor volume, the mean survival time was 74.3 months (range: 63.79-84.88 months) (p<0.05). Among the various factors, histopathologic response and tumor volume change after chemotherapy predicted disease free survival (p<0.05). Change in the tumor volume that was measured with a reproducible method and the histopathologic response after chemotherapy were the important predictors of disease free survival for osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744814      PMCID: PMC2823037          DOI: 10.3349/ymj.2005.46.1.119

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  21 in total

1.  Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience.

Authors:  M Hudson; M R Jaffe; N Jaffe; A Ayala; A K Raymond; H Carrasco; S Wallace; J Murray; R Robertson
Journal:  J Clin Oncol       Date:  1990-12       Impact factor: 44.544

2.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

3.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.

Authors:  G Bacci; S Ferrari; N Delepine; F Bertoni; P Picci; M Mercuri; P Bacchini; A Brach del Prever; A Tienghi; A Comandone; M Campanacci
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

4.  Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping.

Authors:  S L Hanna; D M Parham; D L Fairclough; W H Meyer; A H Le; B D Fletcher
Journal:  Invest Radiol       Date:  1992-05       Impact factor: 6.016

5.  Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma.

Authors:  K H Shin; S H Moon; J S Suh; W I Yang
Journal:  Clin Orthop Relat Res       Date:  2000-07       Impact factor: 4.176

Review 6.  Tumor size and prognosis in aggressively treated osteosarcoma.

Authors:  P Bieling; N Rehan; P Winkler; K Helmke; R Maas; N Fuchs; S Bielack; U Heise; H Jurgens; J Treuner; R Romanowski; U Exner; R Kotz; K Winkler
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

7.  Prognostic factors among 130 patients with osteosarcoma.

Authors:  L Pochanugool; T Subhadharaphandou; M Dhanachai; P Hathirat; D Sangthawan; R Pirabul; S Onsanit; N Pornpipatpong
Journal:  Clin Orthop Relat Res       Date:  1997-12       Impact factor: 4.176

8.  The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy.

Authors:  R M Wellings; A M Davies; P B Pynsent; S R Carter; R J Grimer
Journal:  Clin Radiol       Date:  1994-01       Impact factor: 2.350

9.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.

Authors:  P A Meyers; G Heller; J Healey; A Huvos; J Lane; R Marcove; A Applewhite; V Vlamis; G Rosen
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

10.  Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?

Authors:  H C Holscher; J L Bloem; H J van der Woude; J Hermans; M A Nooy; A H Taminiau; P C Hogendoorn
Journal:  Clin Radiol       Date:  1995-06       Impact factor: 2.350

View more
  3 in total

1.  Outcome of surgical treatment of pelvic osteosarcoma: hospital universiti sains malaysia experience.

Authors:  Ms Ariff; W Zulmi; Wi Faisham; Mz Nor Azman; Ah Nawaz
Journal:  Malays Orthop J       Date:  2013-03

2.  A new relative tumor sizing method in epi-metaphyseal osteosarcoma.

Authors:  Seung Hyun Kim; Kyoo-Ho Shin; Eun Hae Park; Yong Jin Cho; Byoung-Kyu Park; Jin-Suck Suh; Woo-Ick Yang
Journal:  BMC Cancer       Date:  2015-04-15       Impact factor: 4.430

3.  Evaluation of static and dynamic MRI for assessing response of bone sarcomas to preoperative chemotherapy: Correlation with histological necrosis.

Authors:  Priyadarshi Amit; Atul Malhotra; Rahul Kumar; Lokesh Kumar; Dilip Kumar Patro; Sundar Elangovan
Journal:  Indian J Radiol Imaging       Date:  2015 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.